Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
8.1.2025 09:30:00 CET | ACCESS Newswire | Press release
ZAGENO Forms a Strategic Partnership With Hatch.Bio Labs, a Premier Biotech Incubator
BOSTON, MA / ACCESSWIRE / January 8, 2025 / Biotech startups often encounter administrative roadblocks on their path to achieving breakthroughs in life sciences. Today, ZAGENO, the leading AI-powered marketplace for lab supplies, and Hatch.Bio Labs, a premier biotech incubator, join forces to eliminate these challenges.ZAGENO x Hatch.Bio Labs
ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
This strategic partnership empowers Hatch.Bio residents with a streamlined lab supply procurement process, allowing them to prioritize groundbreaking research. ZAGENO's platform offers an Amazon-like shopping experience for lab supplies, featuring:
Effortless Management: Discounted rates, easy price comparison of 5,300+ suppliers, single bill-to options, and automated order tracking.
Dedicated Support: Fast onboarding, procurement best practices, and frequent on-site guidance to maximize platform value.
Reduced Costs: Exclusive discounts for Hatch members, with free access for smaller startups.
"Biotech startups are at the forefront of innovation, but administrative hurdles can delay their progress," says Florian Wegener, CEO and Founder of ZAGENO. "Our partnership with Hatch.Bio simplifies lab supply ordering for their members, saving them valuable time and resources."
James Weis, Hatch.Bio CEO, adds, "This collaboration provides our residents with a critical operational advantage, allowing them to streamline operations and accelerate research."
Through this partnership, Hatch.Bio tenants will gain seamless access to ZAGENO's AI-powered lab supply marketplace. By integrating ZAGENO's platform with Hatch.Bio's facilities and support, this collaboration simplifies procurement, automates tracking, and minimizes administrative tasks, freeing researchers to focus on advancing their research to the clinic.
About ZAGENO
ZAGENO is transforming lab supply procurement with the industry's largest AI-powered marketplace, featuring over 40 million products from 5,300+ global suppliers. Scientists, lab managers, and procurement teams rely on ZAGENO's all-in-one platform for painless lab supply procurement that optimizes budgets and enhances productivity. With automated order and delivery tracking, custom workflows, real-time spend analytics, and offloaded supplier management, ZAGENO empowers labs of all sizes to achieve full lab supply ordering automation. Explore ZAGENO's marketplace and discover how it can streamline your lab supply procurement: www.zageno.com or request access at bit.ly/HatchBio-Labs.
About Hatch.Bio Labs
Hatch.Bio Labs is the premier biotechnology and life sciences incubation platform dedicated to reducing operational barriers for biotechnology and life sciences companies. We provide best-in-class, highly flexible, and cost-effective laboratory and office facilities, natively integrated with comprehensive scientific and operational support and strategic partnerships within a modern technology stack-all to help our resident companies grow more rapidly and efficiently. Our mission is to empower biotech pioneers to develop transformative technologies and advance the pace of biotechnology innovation. For more information and to inquire about becoming a tenant, visit www.hatch.bio.
Contact Information
Stephanie Harold
pr@zageno.com
+1 (857) 477-8479
SOURCE: ZAGENO
View the original press release on accesswire.com
ZAGENO
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Akkodis Completes the Acquisition of SOGECLAIR's Engineering Activities, Strengthening Its Aerospace & Defense Leadership1.10.2026 17:30:00 CEST | Press release
ZÜRICH, SWITZERLAND / ACCESS Newswire / October 1, 2026 / Akkodis, a global digital engineering consulting company, today announced the completion of its acquisition of SOGECLAIR's engineering activities dedicated to Airbus; SOGECLAIR is a leading international engineering and technology company specializing in aerospace, defense and mobility. Image: Akkodis completes acquisition of SOGECLAIR's engineering activities Source: Akkodis The transaction marks a significant milestone in Akkodis' strategy to strengthen its position in the aerospace and defense sector by expanding its capabilities in aerostructures, cabin engineering and manufacturing engineering. It further enhances Akkodis' ability to support customers across the entire product lifecycle, from design and engineering through industrialization and in-service support. With the integration of SOGECLAIR's engineering activities dedicated to Airbus, Akkodis reinforces its position as one of the leading engineering partners to the
Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release
HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy
Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen
Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom